Predicate | Object |
---|---|
rdf:type | |
biopax3:comment |
FGFR2 amplifications have been identified in 10% of gastric cancers, where they are associated with poor prognosis diffuse cancers (Hattori, 1996; Ueda, 1999; Shin, 2000; Kunii, 2008) , and in ~1% of breast cancers (Turner, 2010; Tannheimer, 2000). FGFR2 amplification often occur in conjunction with deletions of C-terminal exons, resulting in expression of a internalization- and degradation-resistant form of the receptor (Takeda, 1999; Cha, 2008, 2009). Amplification affects signaling without altering the intrinsic kinase activity of the receptor. Signaling through overexpressed FGFR2 also shows evidence of being ligand-independent and sensitive to FGFR inhibitors (Lorenzi, 1997; Takeda, 1999; Cha, 2009).
|
biopax3:xref |
http://identifiers.org/pubmed/10626794,
http://identifiers.org/pubmed/11003564,
http://identifiers.org/pubmed/11056689,
http://identifiers.org/pubmed/17505008,
http://identifiers.org/pubmed/18337450,
http://identifiers.org/pubmed/18381441,
http://identifiers.org/pubmed/19103595,
http://identifiers.org/pubmed/20101236,
http://identifiers.org/pubmed/9266968,
http://identifiers.org/pubmed/9816310
|
biopax3:evidenceCode |